Clinical trial
A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability And Pharmacodynamics of Subcutaneous Immunotherapy With DM-101PX in Subjects With Birch Pollen Allergy
NCT07898800 is registered in ClinicalTrials.gov with Desentum Oy as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability And Pharmacodynamics of Subcutaneous Immunotherapy With DM-101PX in Subjects With Birch Pollen Allergy
- Lead sponsor
- Desentum Oy
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- October 29, 2026
- Completion date
- May 31, 2027
- Enrollment
- 40 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
birch pollen allergy
Arms
As registered; 8 arms.
-
DM-101PX for cohort 1
Weekly subcutaneous administration of ascending doses of DM-101PX for 10 weeks with dose escalation starting from 0.2 µg with slightly varying injection volumes.
-
Placebo for cohort 1
Weekly subcutaneous administration of Placebo for 10 weeks
-
Experimental: DM-101PX for cohort 2
Weekly subcutaneous administration of ascending doses of DM-101PX for 10 weeks with dose escalation starting from 0.2 µg with varying injection volumes
-
Placebo for cohort 2
Weekly subcutaneous administration of Placebo for 10 weeks
-
Experimental: DM-101PX for cohort 3
Weekly subcutaneous administration of ascending doses of DM-101PX for 10 weeks with regimens consisting of 2 initial placebo s.c. injections, followed by 8 s.c. injections with escalating doses starting from 0.2 µg and with varying injection volumes.
+3 more arms
Primary endpoints
Registered primary outcome measures; 2 primary.
-
Treatment Emergent Adverse Events
Occurrence of treatment emergent adverse events
-
Adverse Events of Special Interest
Occurrence of local injection site reactions and systemic allergic reactions
Lead sponsor's other trials
Desentum Oy, most recent start first.